These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Risk and prevention of diabetic nephropathy]. Ravera M; Re M; Deferrari G G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442 [TBL] [Abstract][Full Text] [Related]
3. Current update in the management of diabetic nephropathy. Van Buren PN; Toto R Curr Diabetes Rev; 2013 Jan; 9(1):62-77. PubMed ID: 23167665 [TBL] [Abstract][Full Text] [Related]
4. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]
6. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. Krairittichai U; Chaisuvannarat V J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520 [TBL] [Abstract][Full Text] [Related]
7. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney. Bilous R Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685 [No Abstract] [Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Hughes DB; Britton ML Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022 [TBL] [Abstract][Full Text] [Related]
9. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Jacobsen P; Rossing K; Parving HH Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin blockade in type 2 diabetic renal disease. Ruilope LM; Luño J Kidney Int Suppl; 2002 Dec; (82):S61-3. PubMed ID: 12410857 [TBL] [Abstract][Full Text] [Related]
11. Diabetes complications and the renin-angiotensin system. Perkins BA; Aiello LP; Krolewski AS N Engl J Med; 2009 Jul; 361(1):83-5. PubMed ID: 19571288 [No Abstract] [Full Text] [Related]
12. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control]. Shionoiri H; Yasuda G; Takizawa T; Shionoiri F Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741 [No Abstract] [Full Text] [Related]
13. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P; Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120 [TBL] [Abstract][Full Text] [Related]
14. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy. Dalla Vestra M; Simioni N; Masiero A Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580 [TBL] [Abstract][Full Text] [Related]
18. Can two be better than one? Dual RAS blockade in patients with type 2 diabetes and overt nephropathy in the age of ONTARGET and ALTITUDE. Lovshin JA; Cherney DZ Hypertens Res; 2014 Jan; 37(1):4-6. PubMed ID: 24026039 [No Abstract] [Full Text] [Related]
19. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484 [TBL] [Abstract][Full Text] [Related]
20. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. Zeller A; Battegay E Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]